Liquidia (NASDAQ:LQDA) Upgraded by Lifesci Capital to Strong-Buy Rating

Lifesci Capital upgraded shares of Liquidia (NASDAQ:LQDA) to a strong-buy rating in a research note published on Thursday,Zacks.com reports.

Several other research firms also recently issued reports on LQDA. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a report on Saturday. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research report on Thursday. Needham & Company LLC raised their price target on shares of Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright boosted their price objective on Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday. Finally, BTIG Research increased their target price on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.00.

Liquidia Price Performance

Shares of NASDAQ:LQDA traded up $1.51 during trading on Thursday, reaching $36.03. 2,306,542 shares of the company’s stock traded hands, compared to its average volume of 1,900,515. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia has a fifty-two week low of $11.26 and a fifty-two week high of $46.67. The company has a 50-day simple moving average of $37.10 and a 200-day simple moving average of $30.89. The firm has a market cap of $3.13 billion, a PE ratio of -43.41, a P/E/G ratio of 0.60 and a beta of 0.52.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The business had revenue of $92.02 million during the quarter. Liquidia had a negative return on equity of 237.79% and a negative net margin of 43.53%.The firm’s revenue was up 3072.4% on a year-over-year basis. As a group, analysts predict that Liquidia will post -1.51 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Scott Moomaw sold 20,533 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $768,550.19. Following the transaction, the insider directly owned 154,514 shares in the company, valued at $5,783,459.02. The trade was a 11.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Michael Kaseta sold 36,932 shares of Liquidia stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $1,382,364.76. Following the transaction, the chief financial officer owned 350,919 shares in the company, valued at approximately $13,134,898.17. The trade was a 9.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 212,534 shares of company stock worth $7,964,719. 26.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Farallon Capital Management LLC increased its stake in Liquidia by 1.1% during the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after acquiring an additional 90,400 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Liquidia by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after purchasing an additional 52,671 shares during the last quarter. Opaleye Management Inc. raised its holdings in Liquidia by 9.5% in the 2nd quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after buying an additional 215,000 shares during the period. Caprock Group LLC raised its holdings in Liquidia by 9.3% in the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock valued at $61,527,000 after buying an additional 151,832 shares during the period. Finally, TCG Crossover Management LLC acquired a new position in Liquidia in the third quarter valued at about $38,887,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).